ArticleIranian journal of microbiology2025
Biofilm formation and eradication of
Article in Iranian journal of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Synergistic inhibition of agr quorum sensing in methicillin-resistantMicrobiology spectrum · 2026Article
- Engineering a Potent Anti-MRSA Agent: The Development and Characterization of Chimeric Endolysin ZAM-MSC.Iranian biomedical journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Materials and Methods: Biofilms were grown for 24, 48, and 72 hours in Mueller-Hinton broth (MHB), Luria broth (LB), terrific broth (TB), and tryptic soy broth (TSB). The crystal violet assay was used to assess the biomass of the biofilm. The optimal biofilm conditions were then used to test ZAM-CS's activity at different concentrations. Results: MSSA formed the strongest biofilms in TB. MRSA formed stable, high-biomass biofilms in TSB, TB, and LB, while MHB was the least supportive medium for both strains. ZAM-CS significantly reduced biofilm biomass in both MSSA and MRSA (up to 77%). Conclusion: ZAM-CS's rapid and potent anti-biofilm activity at low concentrations highlights its potential as a promising treatment against antibiotic-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.